-+ 0.00%
-+ 0.00%
-+ 0.00%

Relmada Therapeutics Q4 2024 GAAP EPS $(0.62) Beats $(0.70) Estimate

Benzinga·03/27/2025 20:06:29
Listen to the news
Relmada Therapeutics (NASDAQ:RLMD) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate of $(0.70) by 11.43 percent. This is a 26.19 percent increase over losses of $(0.84) per share from the same period last year.